Bricker 2013.

Methods	Pilot randomised controlled trial Location: USA Funding: This study was funded by the Fred Hutchinson Cancer Research Center. Dr. Bricker’s writing of this article was partly supported by a grant from the National Cancer Institute (R01CA166646 01A1). Dr. Heffner’s work on the project was supported by a grant from the National Institute on Drug Abuse (K23DA026517) Recruitment: Participants were recruited by radio and television, web‐based media, social networking sites, paid Internet advertisements, and emails to relevant professional organisations and employers. Participants received USD 10 compensation for completing study assessments at follow‐up. Participants were recruited over a 10‐week period starting June 15, 2010
Participants	Participants (n = 222) ('ACT Webquit.org' n = 111; 'smokefree.gov' n = 111) were aged 18 or older, smoked at least 5 CPD for at least the past 12 months, wanted to quit within the next 30 days, were willing to be randomly assigned, US resident, had weekly access to a high‐speed Internet connection, willing and able to read in English, were not participating in any other smoking cessation interventions, and had never used the smokefree.gov website. No overall baseline characteristic were reported, but the trial arms were balanced on all recorded variables
Interventions	'ACT Webquit.org' was a tailored and interactive Internet intervention, targeting Acceptance and Commitment Therapy's (ACT) core process of values guiding quitting and containing videos of former smokers describing how quitting smoking changed their lives. Helped users apply their core values guiding quitting toward a personalised quit plan, and targeted processes of acceptance, being present, cognitive defusion, and awareness of the difference between one’s self and one’s thoughts. 'smokefree.gov' is a non‐tailored and non‐interactive Internet intervention which involves advice on planning a quit attempt, skills training, advice on pharmacotherapy, and social support for quitting
Outcomes	Outcome data were collected at 3 months. Outcomes were non‐bioverified 30‐day PPA, and the Avoidance and Inflexibility Scale
Notes	Dr. Heffner has in the past served as a consultant for Pfizer. None of the other authors had competing interests to disclose
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Stratified blocked randomisation (with random block sizes), stratifying on gender and current depression
Allocation concealment (selection bias)	Low risk	“Randomised study arm assignments were computer generated and concealed from participants after study eligibility was determined”, “Neither research staff nor study participants had access to upcoming randomised study arm assignments”
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition rates: 44% intervention, 45% control